Abstract
To date, over 2 million patients worldwide have been treated with anti-tumor necrosis factor (TNF) therapies, dramatically improving the treatment outcomes of immune-mediated inflammatory diseases (IMID). Observations from clinicians have identified some curious disconnects between clinical and radiographic outcomes, and the paradoxical occurrence of anti-TNF therapy-induced IMID such as psoriasis or reactivation of uveitis and Crohn's disease. These observations point to the need for a better understanding of the mechanisms underlying the ability of anti-TNF therapies to reduce inflammation and how this is linked to the pathogenesis of IMID. The Journal of Rheumatology
Original language | English (US) |
---|---|
Pages (from-to) | 53-62 |
Number of pages | 10 |
Journal | Journal of Rheumatology |
Volume | 37 |
Issue number | SUPPL. 85 |
State | Published - May 2010 |
Keywords
- Anti-tumor necrosis factor
- Immune-mediated inflammatory diseases
- Pathologic processes
ASJC Scopus subject areas
- Rheumatology
- Immunology and Allergy
- Immunology